Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
about
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisNew targets in psoriatic arthritisAn evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapyReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter studyUpdate on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised plaEffect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).Apremilast for the treatment of psoriatic arthritis.Biological therapies for spondyloarthritis.Emerging drugs for the treatment of axial and peripheral spondyloarthritis.Certolizumab pegol for the treatment of psoriatic arthritis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Novel approaches to biological therapy for psoriatic arthritis.Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis.Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.A novel biological target for the treatment of psoriatic arthritis.Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol.
P2860
Q26764867-729D015C-4D04-4E1B-8D18-989192461C4BQ27693878-35F48FD6-076B-4E4B-A15E-BA3B194B57AEQ28069592-D6F83890-32F8-4591-8CDF-969953E06E83Q28074393-A601803D-5849-4588-B279-748E41AD184BQ30399745-D8A28C88-D467-4A9F-BF13-9C8DCAF932B9Q34228353-09F440C1-48A3-4575-87ED-7FC5C5AFA735Q34818636-1C21D755-03DD-4B1F-AC5A-F239B6E71E03Q34818891-4FC87048-007C-4921-9DCA-E38143F7FB01Q36182389-A31C3E38-1457-4D6D-84E1-6C3F51E2C252Q37465416-2AD7DC6B-480E-4C73-8A51-DC321BD76B03Q37465550-B69C89B2-2CF8-458D-AFE5-3393D393DEEFQ38202205-12B49CBA-C4C8-4F1C-8E0A-5BDDB16753AAQ38217223-174F0A40-628D-4033-96C5-79239F0EF658Q38313266-23BAFB85-D56D-4A8E-9A30-5CD935242F39Q38344194-03DD7433-7DC8-42CF-9051-237C7AE61532Q38630548-6B36D347-97EA-42A1-BAFE-3EE29AC0CC47Q38634276-6F9217BF-4FFD-4B84-9245-080CF2FD3B9EQ38667430-ABAE12CE-2F73-4F3B-90C6-F0A2F5D5A96CQ38972531-90D822BD-2A62-4DC3-9318-97FF4D41F0E6Q38998373-6A43082F-1B83-4C51-99FF-958A9C77333EQ39328197-E6307AA4-187B-41BD-8AC2-F095C4CEB3CBQ40740817-5088FCAA-A5B1-48FF-B72B-0D9C8AC6BA56Q44268181-500FF72D-F593-4163-B43F-6E8C5C5BFB8DQ47114261-C1610246-BCAC-4DF2-A65D-D0D4BE9E73A5Q51738114-62AC7564-596D-44CD-919F-7F4245EAEA68Q53164680-514DA3CF-DFA2-406A-B855-7D18C5785CEB
P2860
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of different imputation ...... d study of certolizumab pegol.
@en
Effect of different imputation ...... d study of certolizumab pegol.
@nl
type
label
Effect of different imputation ...... d study of certolizumab pegol.
@en
Effect of different imputation ...... d study of certolizumab pegol.
@nl
prefLabel
Effect of different imputation ...... d study of certolizumab pegol.
@en
Effect of different imputation ...... d study of certolizumab pegol.
@nl
P2093
P2860
P1476
Effect of different imputation ...... d study of certolizumab pegol.
@en
P2093
D van der Heijde
F Woltering
J Wollenhaupt
R Fleischmann
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-203697
P407
P577
2013-08-13T00:00:00Z